8 Biotechnology Stocks to Buy Now

Advertisement

The grades of eight biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.

Idera Pharmaceuticals, Inc. (IDRA) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. Idera Pharmaceuticals is engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like Receptors (TLRs) to treat infectious diseases, autoimmune and inflammatory diseases, cancer, asthma and allergies, and for use as vaccine adjuvants. In Portfolio Grader’s specific subcategory of Sales Growth, IDRA also gets an A. For more information, get Portfolio Grader’s complete analysis of IDRA stock.

This week, Tekmira Pharmaceuticals Corporation (TKMR) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Tekmira Pharmaceuticals is a biopharmaceutical company. For more information, get Portfolio Grader’s complete analysis of TKMR stock.

MediciNova, Inc.’s (MNOV) ratings are looking better this week, moving up to an A from last week’s B. Medicinova acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.

Pharmacyclics, Inc. (PCYC) boosts its rating from a C to a B this week. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. For more information, get Portfolio Grader’s complete analysis of PCYC stock.

This is a strong week for Emergent BioSolutions Inc. (EBS). The company’s rating climbs to B from the previous week’s C. Emergent BioSolutions develops and produces immunobiotics, pharmaceutical products that assist the body’s immune system to prevent or treat disease. For more information, get Portfolio Grader’s complete analysis of EBS stock.

OPKO Health, Inc. (OPK) gets a higher grade this week, advancing from a C last week to a B. OPKO Health is involved in the discovery, development, and commercialization of pharmaceutical products, vaccines, and diagnostic products. For more information, get Portfolio Grader’s complete analysis of OPK stock.

This week, Regeneron Pharmaceuticals, Inc.’s (REGN) ratings are up from a B last week to an A. Regeneron Pharmaceuticals researches, develops and commercializes therapeutics to treat human disorders and conditions. For more information, get Portfolio Grader’s complete analysis of REGN stock.

Ambit Biosciences Corp. (AMBI) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/01/8-biotechnology-stocks-to-buy-now-idra-tkmr-mnov/.

©2024 InvestorPlace Media, LLC